As many as 20,000 patients in England and Wales with severe rheumatoid arthritis (RA) could soon benefit from RoActemra intravenous (IV) monotherapy, after the National Institute for Health and Care Excellence (NICE) issued a positive Final Appraisal Determination (FAD) today, recommending the medicine for use on the NHS.1 The decision is based on a dossier of data that included results which show RoActemra helps almost four times as many patients achieve remission than those treated with a leading anti-TNF monotherapy. The guidance brings England and Wales in line with Scotland, where RoActemra has been available as monotherapy or in combination with methotrexate to Scottish patients for a year.
